ALISSA SOBIERAJ: Open Payments
NPI 1619073459 · BRIDGEPORT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 26 payments from 14 companies in 2025. Trend: 2023 $36 · 2024 $452 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 2 | $89 |
| Novo Nordisk Inc | 5 | $80 |
| Lilly USA, LLC | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| ABBVIE INC. | 2 | $35 |
| Dexcom, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
Products named: AVEIR, Wegovy, MOUNJARO, VOQUEZNA, CAPLYTA, Dexcom G6 Transmitter, Veozah, SHINGRIX.
Industry payments across TX — which companies pay providers there.
